- Tonix Pharmaceuticals Holding Corp TNXP announced that it received the official written response from a Type B pre-Investigational New Drug (IND) meeting with the FDA for its COVID-19 vaccine candidate.
- Based on the response, the Company expects to begin a Phase 1 study in 1H of 2022.
- TNX-1800 is a live modified horsepox virus vaccine designed to express the Spike protein of the SARS-CoV-2 virus and elicit a predominant T cell response.
- Related Content: Tonix Pharma To Start Mid-Stage Long COVID Trial In Q4.
- Price Action: TNXP shares are up 0.02% at $0.66 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
